



08030995

SECURITIES AND EXCHANGE COMMISSION  
Washington, D. C. 20549

**OMB APPROVAL**

OMB Number 3235-0123  
Expires February 28, 2010  
Estimated average burden  
Hours per response 12.00

**ANNUAL AUDITED REPORT  
FORM X-17A-5  
PART III  
FACING PAGE**

**SEC FILE NUMBER  
8 - 65359**

Information Required of Brokers and Dealers Pursuant to Section 17 of the  
Securities Exchange Act of 1934 and Rule 17a-5 Thereunder

003  
Processing  
MAR 31 2008

REPORT FOR THE PERIOD BEGINNING JANUARY 1, 2007 AND ENDING DECEMBER 31, 2007

Washington, DC  
103

**A. REGISTRANT IDENTIFICATION**

NAME OF BROKER-DEALER:

**OFFICIAL USE ONLY**

BIO-IB, INC.

ADDRESS OF PRINCIPAL PLACE OF BUSINESS: (Do not use P. O. Box No.)

600 LEXINGTON AVENUE - 29<sup>TH</sup> FLOOR

NEW YORK,

NEW YORK

(City)

(State)


(Zip Code)

NAME AND TELEPHONE NUMBER OF PERSON TO CONTACT IN REGARD TO THIS REPORT

KATHY EFREM

(212) 509 - 7800

(Area Code - Telephone No.)



**B. ACCOUNTANT IDENTIFICATION**

INDEPENDENT PUBLIC ACCOUNTANT whose opinion is contained in this Report\*

LERNER & SIPKIN, CPAs, LLP

132 Nassau Street, Suite 1023

New York

NY

10038

Certified Public Accountant

**PROCESSED**

**FOR OFFICIAL USE ONLY**

APR 03 2008

THOMSON  
FINANCIAL

\*Claims for exemption from the requirement that the annual report be covered by the opinion of an independent public accountant must be supported by a statement of facts and circumstances relied on as the basis for the exemption. See section 240.17a-5(e)(2).

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

SEC 1410 (06-02)

AB\*  
4/1


OK  
4/2

OATH OR AFFIRMATION

I, **THERESA DOWLING**, swear (or affirm) that, to the best of my knowledge and belief, the accompanying financial statement and supporting schedules pertaining to the firm of **BIO-IB, INC., as of DECEMBER 31, 2007**, are true and correct. I further swear (or affirm) that neither the company nor any partner, proprietor, member, principal officer or director has any proprietary interest in any account classified solely as that of a customer, except as follows:

NONE

*N/A*



X

*[Handwritten Signature]*

Signature

*President*

Title

X *Debra L. Sanchez 03/25/08*  
Notary Public

This report\*\* contains (check all applicable boxes):


- (a) Facing page.
- (b) Statement of Financial Condition.
- (c) Statement of Income (Loss).
- (d) Statement of Cash Flows.
- (e) Statement of Changes in Stockholders' Equity or Partners' or Sole Proprietor's Capital.
- (f) Statement of Changes in Liabilities Subordinated to Claims of Creditors.
- (g) Computation of Net Capital.
- (h) Computation for Determination of Reserve Requirements Pursuant to Rule 15c3-3.
- (i) Information Relating to the Possession or Control requirements under rule 15c3-3.
- (j) A Reconciliation, including appropriate explanation, of the Computation of Net Capital Under Rule 15c3-1 and the Computation for Determination of the reserve requirements Under Exhibit A of Rule 15c3-3.
- (k) A Reconciliation between the audited and unaudited Statements of Financial Condition with respect to methods of consolidation.
- (l) An Oath or Affirmation.
- (m) A copy of the SIPC Supplemental Report.
- (n) A report describing any material inadequacies found to exist or found to have existed since the date of the previous audit.
- (o) Independent Auditors' Report.

\*\* For conditions of confidential treatment of certain portions of this filing, see section 240.17a-5(e)(3).

I, **THERESA DOWLING**, swear that to the best of my knowledge and belief, the accompanying financial statements and supporting schedule(s) pertaining to the Firm of **BIO-IB, INC.**, as of **DECEMBER 31, 2007**, are true and correct.


I further swear that neither the Company nor any partner, proprietor, principal officer, director or member has any proprietary interest in any account classified solely as that of customer, except as follows:

No Exceptions  
-----

  
-----  
(Signature)

*President*  
-----  
(Title)

*Debra L. Sanchez 12/25/08*  
(Notary Public)



2008  
STATE OF MARYLAND  
RECEIVED  
MAY 14 2008  
STATE OF MARYLAND  
RECEIVED

**BIO-IB, INC.**  
**STATEMENT OF FINANCIAL CONDITION**

**DECEMBER 31, 2007**

**BIO-IB, INC.**  
**STATEMENT OF FINANCIAL CONDITION**  
**DECEMBER 31, 2007**

**ASSETS**

Cash and cash equivalents	\$ 12,530
Equipment - net of accumulated depreciation of \$1,347. (Note 2(e))	<u>936</u>
Total assets	<u>\$ 13,466</u>

**LIABILITIES AND STOCKHOLDERS' EQUITY**

**Liabilities:**

Accounts payable and accrued expenses	\$ 4,300
Total liabilities	<u>4,300</u>

**Commitments and Contingencies (Note 4)**

**Stockholders' equity (Note 6)**

Common stock, no par value; 1,500 shares authorized, issued and outstanding	68,085
Additional paid-in capital	65,210
Retained (deficit)	<u>(124,129)</u>
Total stockholders' equity	<u>9,166</u>
Total liabilities and stockholders' equity	<u>\$ 13,466</u>

*The accompanying notes are an integral part of these statements.*

**BIO-IB, INC.**  
NOTES TO FINANCIAL STATEMENTS  
DECEMBER 31, 2007

**Note 1- Nature of Business**

Bio-IB, Inc. (The "Company"), a Delaware corporation, is a broker/dealer of securities registered with the Securities and Exchange Commission and is a member of the Financial Industry Regulatory Authority. The Company was formed primarily to advise European micro-cap and small-cap companies primarily in the biotechnology and information technology sectors in the private placement of securities to United States institutions.

Through December 2007, the Company was wholly owned by Axcel Capital Partners SArl. Ltd. ("Ltd"), a Swiss corporation. Since December 2007 First London Securities, the majority holder of which was the majority holder of Ltd, owns the Company.

**Note 2- Summary of Significant Accounting Policies**

**a) Revenue Recognition**

Commission income (and the recognition of related income and expenses) is recorded at the time the commissions are realized.

**b) Income Taxes**

The Company accounts for income taxes under SFAS No. 109, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets if it is more likely than not that such assets will not be realized.

**c) Cash and Cash Equivalents**

For the purpose of the statement of cash flows, the Company considers money market instruments to be cash and cash equivalents. The Company maintains cash in bank accounts which, at times, may exceed federally insured limits or where no insurance is provided. The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

**d) Use of Estimates**

Management uses estimates and assumptions in preparing financial statements. Those estimates and assumptions affect the reported amounts of assets and liabilities, and the reported amounts of revenues and expenses.

**e) Equipment**

Equipment is carried at cost and is depreciated over a useful life of 5-7 years using the straight line-method.

**BIO-IB, INC.**  
NOTES TO FINANCIAL STATEMENTS  
DECEMBER 31, 2007

**Note 3- Special Payment from Financial Industry Regulatory Authority**

Included in miscellaneous income, in the statement of operations, is a non-recurring \$35,000 payment received in connection with the merger of the regulatory functions of the New York Stock Exchange and the National Association of Securities Dealers.

**Note 4- Management Agreement**

The Company entered into a Management Agreement (the "Agreement") with Ltd. whereby the Company pays Ltd. a management fee, as base compensation for services provided to the Company, including, but not limited to, financial services management, information systems, office facilities and administrative services. Additionally, Ltd. provides for overhead expenses, which include, but are not limited to, rent, office equipment and supplies, secretarial expenses, charges for furniture and equipment, utilities, salaries, and expenses of directors, employees and agents. The management fee can be adjusted by Ltd. upon 30 days' prior notice to the Company. In addition to the management fee, Ltd. may charge the Company for certain overhead expenses, as determined by the board of directors of Ltd. As per the Agreement, the management fee has been waived by Ltd. until the Company is otherwise notified.

In 2007, Ltd. paid the company \$23,605 of advisory fee income.

The agreement has been assigned to the new owner (Note 1).

**Note 5- Income Taxes**

At December 31, 2007, the Company had a net operating loss carryforward of approximately \$117,000 for income tax purposes. This carryforward will expire from 2018. Since it is doubtful that such carryforward will be utilized in the near term, a valuation allowance of \$17,600 has been established to offset the deferred tax asset arising from this carryforward. Therefore, no deferred tax assets have been recorded on the accompanying statement of financial condition.

**Note 6- Net Capital Requirement**

The Company is subject to the Securities and Exchange Commission's Uniform Net Capital Rule (Rule 15c3-1), which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 1500%. At December 31, 2007, the Company's net capital of \$8,192 was \$3,192 in excess of the required net capital of \$5,000.



**LERNER & SIPKIN**  
CERTIFIED PUBLIC ACCOUNTANTS LLP

132 Nassau Street, New York, NY 10038 Tel 212.571.0064 / Fax 212.571.0074  
E-mail: LS@lernerstipkin.com

**INDEPENDENT AUDITORS' REPORT**

To the Officers and Directors of  
Bio-IB, Inc.  
600 Lexington Avenue – 29<sup>th</sup> Floor  
New York, NY 10022

We have audited the accompanying statement of financial condition of Bio-IB, Inc. as of December 31, 2007. This financial statement is the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the statement of financial condition referred to above presents fairly, in all material respects, the financial position of Bio-IB, Inc. as of December 31, 2007, in conformity with accounting principles generally accepted in the United States of America.

*Lerner & Sipkin CPAs LLP*  
Lerner & Sipkin, CPAs, LLP  
Certified Public Accountants (NY)

New York, NY  
March 19, 2008

**END**